{"related:MS-2CTao5YcJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5":[{"title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal …","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2005.02.2574","authors":["RJ Motzer","RJ Motzer MD Michaelson","RJ Motzer MD Michaelson BG Redman…"],"year":2006,"numCitations":1986,"pdf":"/scholar?output=instlink&q=info:MS-2CTao5YcJ:scholar.google.com/&hl=en&as_sdt=0,5&scillfp=15423635811831188084&oi=lle","citationUrl":"http://scholar.google.com/scholar?cites=9792417914831646513&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:MS-2CTao5YcJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9792417914831646513&hl=en&as_sdt=0,5","publication":"ascopubs.org","p":1,"exp":1596876833732},{"title":"Sunitinib in patients with metastatic renal cell carcinoma","url":"https://jamanetwork.com/journals/jama/article-abstract/202955","authors":["RJ Motzer","RJ Motzer BI Rini","RJ Motzer BI Rini RM Bukowski","RJ Motzer BI Rini RM Bukowski BD Curti","RJ Motzer BI Rini RM Bukowski BD Curti DJ George…"],"year":2006,"numCitations":1471,"pdf":"https://jamanetwork.com/journals/jama/articlepdf/202955/jpc60004.pdf","citationUrl":"http://scholar.google.com/scholar?cites=16502718046409290145&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:oXGnyKBuBeUJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16502718046409290145&hl=en&as_sdt=0,5","publication":"jamanetwork.com"},{"title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","url":"ftp://ftp.biostat.wisc.edu/pub/chappell/641/notes.week13and14/JCO-2006-Ratain-2505-12.pdf","authors":["MJ Ratain","MJ Ratain TIM Eisen","MJ Ratain TIM Eisen WM Stadler…"],"year":2006,"numCitations":1225,"pdf":"ftp://ftp.biostat.wisc.edu/pub/chappell/641/notes.week13and14/JCO-2006-Ratain-2505-12.pdf","citationUrl":"http://scholar.google.com/scholar?cites=11052430021036642189&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:jY_AvIseYpkJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11052430021036642189&hl=en&as_sdt=0,5","publication":"biostat.wisc.edu"},{"title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa065044","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson P Tomczak…"],"year":2007,"numCitations":6133,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa065044","citationUrl":"http://scholar.google.com/scholar?cites=12674526305022444340&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:NAM1m4X25K8J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12674526305022444340&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma","url":"http://nlp.case.edu/public/data/TargetedToxicity_JCOFullText/goldstandard/2013-07-19_04-48-54_tagged.html","authors":["B Escudier","B Escudier J Roigas","B Escudier J Roigas S Gillessen…"],"year":2009,"numCitations":201,"pdf":"http://nlp.case.edu/public/data/TargetedToxicity_JCOFullText/goldstandard/2013-07-19_04-48-54_tagged.html","citationUrl":"http://scholar.google.com/scholar?cites=8333850791008098277&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:5VclySPJp3MJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8333850791008098277&hl=en&as_sdt=0,5","publication":"nlp.case.edu"},{"title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","url":"http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.997.6153&rep=rep1&type=pdf","authors":["S Faivre","S Faivre C Delbaldo","S Faivre C Delbaldo K Vera","S Faivre C Delbaldo K Vera C Robert…"],"year":2006,"numCitations":1258,"pdf":"http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.997.6153&rep=rep1&type=pdf","citationUrl":"http://scholar.google.com/scholar?cites=11982878484495275394&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ghUDX368S6YJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11982878484495275394&hl=en&as_sdt=0,5","publication":"Citeseer"},{"title":"A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa021491","authors":["JC Yang","JC Yang L Haworth","JC Yang L Haworth RM Sherry","JC Yang L Haworth RM Sherry P Hwu…"],"year":2003,"numCitations":3244,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa021491","citationUrl":"http://scholar.google.com/scholar?cites=15259092479126344060&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:fBEpfcMvw9MJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15259092479126344060&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal …","url":"https://www.sciencedirect.com/science/article/pii/S0960076007002518","authors":["A Polyzos"],"year":2008,"numCitations":55,"citationUrl":"http://scholar.google.com/scholar?cites=12348260152890514829&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:jV0mZy_VXasJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12348260152890514829&hl=en&as_sdt=0,5","publication":"Elsevier"},{"title":"Sorafenib in advanced clear-cell renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa060655","authors":["B Escudier","B Escudier T Eisen","B Escudier T Eisen WM Stadler…"],"year":2007,"numCitations":5345,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa060655","citationUrl":"http://scholar.google.com/scholar?cites=4193023401754303534&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:Lhx3fJGcMDoJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4193023401754303534&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors …","url":"https://clincancerres.aacrjournals.org/content/9/1/327.short","authors":["DB Mendel","DB Mendel AD Laird","DB Mendel AD Laird X Xin","DB Mendel AD Laird X Xin SG Louie…"],"year":2003,"numCitations":2141,"pdf":"https://clincancerres.aacrjournals.org/content/clincanres/9/1/327.full.pdf","citationUrl":"http://scholar.google.com/scholar?cites=7899970790450967782&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:5rTK_JNVom0J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=7899970790450967782&hl=en&as_sdt=0,5","publication":"AACR"}]}